Nov. 15 at 2:22 AM
$PHIO buy the dip, the have excellent fundamentals
PHIO’s data is excellent — multiple 100% tumor clearances
• Safety is clean
• Trial hit max dose and final cohort
• Cash runway extended to 2027
• Drop to
$1.24 is purely trader and warrant-selling noise
• Biotechs drop after news — then rally on next milestones
• Expect recovery to
$2–3 in coming months
• Expect bigger move
$4–8 on Phase 2 transition
Short-Term (1–4 weeks)
📌 As warrant selling dries up → stabilization
Expected price:
$1.40 –
$1.80
Medium-Term (1–3 months)
Catalysts:
• More patients treated in Cohort 5
• A Phase 2 trial design update
• Conference presentations (AACR 2026 abstract cycle is soon)
• Partnership rumors (PHIO has been presenting aggressively)
Expected price:
$2.00 –
$3.00
Major Catalyst (3–12 months)
The next true inflection point:
➡️ Phase 1b Final Data Set (full 18–25 patients)
➡️ Movement to Phase 2
➡️ Partnering / licensing deal
➡️ FDA interaction update
Expected price:
$4 –
$8
